A. Wree

Th2 Cell Activation in Chronic Liver Disease Is Driven by Local IL33 and Contributes to IL13-Dependent Fibrogenesis

H. Zimmermann, M. Berres, J. Reissing, 2023, Cellular and molecular gastroenterology and hepatology.

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

T. Luedde, C. Strassburg, C. Roderburg, 2023, BMC Cancer.

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort

T. Luedde, S. Loosen, F. Tacke, 2023, Alimentary pharmacology & therapeutics.